Related Experiment Video
Updated: Nov 15, 2025

Nephrotoxin Microinjection in Zebrafish to Model Acute Kidney Injury
Published on: July 17, 2016
COVID-19 and the Kidney: A Worrisome Scenario of Acute and Chronic Consequences
Luis Sanchez-Russo1, Marzuq Billah1, Jorge Chancay1
1Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Insights
Acute kidney injury (AKI) in COVID-19 patients, or CoV-AKI, is common and linked to higher mortality. Management challenges include increased demand for kidney replacement therapies and exploring novel treatments like peritoneal dialysis.
Area of Science:
- Nephrology
- Infectious Diseases
- Critical Care Medicine
Background:
- Acute kidney injury (AKI) is a frequent complication of COVID-19.
- COVID-19-related AKI (CoV-AKI) is associated with increased mortality.
- The exact causes of CoV-AKI are still under investigation, with evidence suggesting direct viral and indirect injury to the kidneys.
Purpose of the Study:
- To highlight the clinical presentation and management challenges of CoV-AKI.
- To discuss the impact of CoV-AKI on healthcare systems, particularly kidney replacement therapies.
- To explore alternative treatment strategies for critically ill patients with CoV-AKI.
Main Methods:
- Review of existing literature on CoV-AKI.
- Analysis of histopathologic findings in COVID-19 patients with kidney injury.
- Discussion of clinical observations and therapeutic approaches, including acute peritoneal dialysis.
Main Results:
- CoV-AKI significantly increases mortality risk in COVID-19 patients.
- The high incidence of CoV-AKI strains healthcare resources for kidney replacement therapies.
- Alternative treatments like peritoneal dialysis are being explored for severe cases.
Conclusions:
- CoV-AKI presents significant clinical and resource challenges.
- Long-term outcomes for survivors of CoV-AKI remain a concern, with a notable proportion requiring ongoing kidney support.
- Healthcare professionals must be prepared to manage CoV-AKI to mitigate its impact on patients and renal services.
Abstract:
Acute kidney injury (AKI) is a common finding in patients with coronavirus disease 2019 (COVID-19) and has been associated with higher rates of death when compared to COVID-19 patients without kidney injury. Whereas the definitive pathogenesis of COVID-19-related AKI (CoV-AKI) is not clear, histopathologic evidence seems to point at multiple etiologies for the disease, including indirect and direct viral kidney injury. The high incidence of CoV-AKI, along with the aggressive clinical presentation of this entity, have increased the demands for kidney replacement therapies, rapidly overwhelming the supplies of healthcare systems even in major tertiary care centers. As a result, nephrologists have come up with alternatives to maximize the efficiency of treatments and have developed non-conventional therapeutic alternatives such as the implementation of acute peritoneal dialysis for critically ill patients. The long-term implications of CoV-AKI are yet unknown, though early studies suggest that around one third of the patients who survive will remain dependent on kidney replacement therapy. Nephrologists and healthcare workers need to be familiar with the clinical presentation and therapeutic challenges of CoV-AKI in order to develop strategies to mitigate the burden of the disease for patients, and for services providing kidney replacement therapies.
Related Concept Videos
Chronic Kidney Disease I: Introduction
Acute Kidney Injury III: Clinical Manifestations
Acute Kidney Injury I: Introduction
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury II: Pathophysiology
Chronic Kidney Disease II: Clinical Manifestations

